SIMPPLE Ltd. (NASDAQ: SPPL) (“SIMPPLE” or “the Company”), a leading technology provider and innovator in the facilities ...

Company in full compliance for continued listingMIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” ...

Portage Biotech confirms compliance with Nasdaq listing requirements, advancing its immuno-oncology pipeline. Quiver AI Summary. Portage Biotech Inc. announced that it has received formal notice ...

Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from ...

New Horizon Aircraft (NASDAQ: HOVR), doing business as Horizon Aircraft (“Horizon Aircraft” or the “Company”), an advanced aerospace engineering company and developer of one the world’s first hybrid ...

Earlyworks Co., Ltd. (Nasdaq: ELWS) (the 'Company” or 'Earlyworks”), a Japanese company operating its proprietary private ...

Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”), announced today that on June ...

Rocky Mountain Chocolate Factory, Inc. (Nasdaq: RMCF) (the “Company”, “we”, or “RMCF”), America’s ChocolatierTM and a leading franchiser of a premium chocolate and confectionary retail store concept, ...

Investing.com -- Unity Biotechnology Inc (NASDAQ: UBX) stock plunges 45% after receiving notification that Nasdaq plans to delist the company’s securities, citing concerns that it has become a "public ...

Fangdd Network Group Ltd. (NASDAQ: DUO) (“DUO” or the “Company”), today announced that on June 24, 2025, the Company received written notice from the Listing Qualifications Department of The Nasdaq ...

Bone Biologics was notified by Nasdaq on April 7, 2025 that it was not in compliance with the Rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive ...

"We are confident that our plan demonstrates our ability to regain compliance with Nasdaq's listing requirements, an important step that reflects our commitment to advancing our lead clinical program, ...